3 Firms Steer Chinese Pharma Co.'s $288M Hong Kong IPO
China-based cancer drug developer InnoCare said Friday it raised HK$2.2 billion ($288 million) in an oversubscribed initial public offering steered by Davis Polk & Wardwell LLP, Commerce & Finance Law Offices...To view the full article, register now.
Already a subscriber? Click here to view full article